A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)]
← catalyst calendarNCT05895786 · readout in 343 d
Sponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
318estimated
Sites
146
Countries
Argentina, Bulgaria, China +17
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-05-20 | actual | When the study began enrolling |
| Primary completion | 2027-07-28 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-07-28 | estimated | The whole study's end, after follow-up |
| First posted | 2023-06-09 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-01 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Myositis
Interventions
- Drug: PF-06823859
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFModerate change in Total Improvement Score (TIS)
measured 24 weeks outside of the United States (US) and 52 weeks in the US
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed